Emerging research suggest this peptide, a dual activator targeting both incretin and glucose-dependent insulinotropic polypeptide , may provide a significant advancement for obesity loss . Early patient tests have indicated impressive losses in body tissue, conceivably exceeding other body composition therapies . However , more study is required to